Stem cell doses in knee osteoarthritis


Autores/as

  • Samuel Eduardo Trujillo Henao Universidad Tecnológica de Pereira
  • Julieta Henao Bonilla Universidad Tecnológica de Pereira
  • Gustavo Adolfo Marín S. Servicios Integrales de Salud Orthotrauma S.A.S
  • Camila Vargas M. Universidad Tecnológica de Pereira
  • Jainer Aranzazu Centro de Células Madre y Biotecnología CEMAB
  • Bibiana Murillo G Universidad Tecnológica de Pereira
  • Camilo Marín G Fundación Universitaria Ciencias de la Salud

DOI:

https://doi.org/10.22517/25395203.21261

Palabras clave:

growth factors, osteoarthritis, quality of life, regenerative medicine, stem cells

Resumen

Osteoarthritis (OA) is a degenerative disease where conventional treatment includes drugs, physiotherapy, or prostheses. Stem cells and growth factors are a promising option in controlling symptoms, functional improvement and cartilage regeneration; however, many treatment details have not been specified, such as type and number of stem cells that should be applied to obtain optimal results. In this study we sought to compare effectiveness, safety and costs of two doses (1X107vs 3X107) of adipose tissue derived stem cells (ADSC), applied intra-articularly. Ten patients, with knee OA grades II and III, were randomized to receive 10 (n=5) or 30 million (n=5) of autologous ADSCs. At baseline and 6 to 10 months after injection, they were evaluated according to clinical (medical evaluation, WOMAC scale, quality of life) and paraclinical criteria (arthroscopy, resonance, biopsy). In terms of effectiveness and safety there were no differences observed among the two dosage groups since all patients had improvement according to medical criteria and the WOMAC scale (P=0,001); in the arthroscopic control, 7 patients had "good/very good" response, 1 "neutral" and 2 forwent control; biopsies confirm joint regeneration, although there were no differences in the before and after magnetic resonances. In knee osteoarthritis, the application of 10 or 30 million ADSCs was equally effective and safe; however, the protocol with 10 million cells does not require in vitro expansion, requires less time, is simpler and has a lower cost. This study shows good reason to undertake randomized clinical trials to gain higher quality evidence.

Descargas

Los datos de descargas todavía no están disponibles.

Biografía del autor/a

Samuel Eduardo Trujillo Henao, Universidad Tecnológica de Pereira

Docente Titular, Departamento de Ciencias Básicas Médicas

Julieta Henao Bonilla, Universidad Tecnológica de Pereira

Docente Titular Universidad Tecnológica de Pereira, Programa de Medicina de la Facultad Ciencias de la Salud

Gustavo Adolfo Marín S., Servicios Integrales de Salud Orthotrauma S.A.S

Médico Especialista en Ortopedia y Traumatología, Docente del Programa de Medicina de La Fundación Universitaria de las Américas,

Camila Vargas M., Universidad Tecnológica de Pereira

Estudiante del Programa de Medicina Universidad Tecnológica de Pereira

Jainer Aranzazu, Centro de Células Madre y Biotecnología CEMAB

Biólogo del Centro de Células Madre y Biotecnología CEMAB

Bibiana Murillo G, Universidad Tecnológica de Pereira

Docente Titular Universidad Tecnológica de Pereira, Directora del Departamento de Ciencias Básicas Médicas de la Facultad Ciencias de la Salud

Camilo Marín G, Fundación Universitaria Ciencias de la Salud

Estudiante segundo año de la Especialización en Ortopedia de la Fundación Universitaria Ciencias de la Salud

Descargas

Publicado

2020-06-12

Cómo citar

Trujillo Henao, S. E., Henao Bonilla, J., Marín S., G. A., Vargas M., C., Aranzazu, J., Murillo G, B., & Marín G, C. (2020). Stem cell doses in knee osteoarthritis. Revista Médica De Risaralda, 25(2). https://doi.org/10.22517/25395203.21261

Número

Sección

Artículo original